Akari Therapeutics advances research on novel PH1 payload for targeted cancer therapy - PharmaTimes Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody drug conjugates

#oncology #immunotherapy #AkariTherapeutics #novelPH1payload #targetedcancertherapy #PH1 #antibodydrugconjugates #ADCs #oncogenicmutations #DNAsplicing #neoantigens #missplicedproteins #effluxtransporters #oncogenicdrivers #PH1spliceosomemodulatorpayload
pharmatimes.com/news/akari-t...